LifeMine Raises $263M to Advance LIFE-001, a Fungi-Derived Drug Designed to Fix Organ Transplant Rejection

LifeMine Therapeutics, a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company, raised $263 million across a $75 million Series D (closed Q4 2025) and a $188 million Series E (closed July 2026). The Series E was led by Milky Way Investments, with new investors Bezos Expeditions, Gates Frontier, and RA Capital Management participating alongside existing investors GV, LoLa Capital Partners, GlaxoSmithKline, Invus, and ARCH Venture Partners. The combined $263 million in financing is the largest private raise in the calcineurin inhibitor category and brings LifeMine's total funding to over $400 million.

What LifeMine Builds

LifeMine was founded by Greg Verdine, a Harvard chemistry professor and pioneering drug developer whose laboratory pioneered the discovery of natural product-derived therapeutics from fungi and other organisms. The company's lead asset, LIFE-001, is a calcineurin activation inhibitor designed to replace the immunosuppressant drugs currently used in organ transplant recipients to prevent rejection. The existing standard of care, drugs like tacrolimus and cyclosporine, prevents transplant rejection by suppressing the immune system through the calcineurin pathway but causes significant toxicity including kidney damage, hypertension, diabetes, and increased cancer risk. These side effects are paradoxical: the drugs that save the transplanted organ cause damage to the patient's other organs over the long term.

LIFE-001 addresses this by inhibiting calcineurin through a different mechanism that avoids the immunophilin-dependent pathway responsible for the legacy drug toxicities. The compound is derived from a fungal natural product, continuing a tradition in transplant medicine that dates to the discovery of cyclosporine from a Norwegian soil fungus in the 1970s. LIFE-001 is delivered as a long-acting injectable, potentially offering monthly or quarterly dosing rather than the twice-daily oral regimens of current drugs.

Who the Investors Are

The investor list is notable for its breadth and quality. RA Capital Management specialises in public-private crossover biotech investments. GV is Google's life science and technology venture arm. GlaxoSmithKline's participation as a corporate venture investor signals potential strategic interest from a major pharmaceutical company. Bezos Expeditions and Gates Frontier are the family office investment vehicles of Jeff Bezos and Bill Gates respectively; both have established track records in longevity, health technology, and biopharmaceutical investments. Milky Way Investments as Series E lead suggests a crossover fund positioning for eventual public market entry.

What This Means for Biotech Founders

LifeMine's financing structure is instructive for founders raising capital for long-development-cycle biotech programs. The company raised a $75 million Series D to generate specific clinical proof points, then returned to market for a larger $188 million Series E once those data were available. That staged approach preserved valuation optionality: by demonstrating clinical progress before raising the larger round, LifeMine attracted a higher-quality investor syndicate at better terms than a larger earlier raise would have achieved. Understanding your runway between each clinical milestone is the core financial planning discipline for biotech founders: it determines how much buffer you have to generate the data package that unlocks the next round. Biotech founders can see active life science investors on AngelLinx for funds investing at each stage of the clinical development pipeline.

The combination of corporate strategic investors (GSK), crossover public-market funds (RA Capital), and mission-driven family offices (Bezos, Gates) in a single round is an optimal syndicate for a clinical-stage biotech. Each investor type provides a different form of non-capital value: strategic distribution and licensing options (GSK), public market transition support (RA Capital), and long-horizon patient capital (family offices). For additional context on how biotech companies structure their capital raises across development stages, see our AngelLinx newsroom coverage of other life science raises in the August window. Founders ready to build their biotech investor relationships can also see who is currently raising on the AngelLinx live listing.

Find biotech and life science investors actively building pipelines on AngelLinx @ angellinx.ai/register.

AngelLinx Intelligence | angellinx.ai